StockData

Cryoport vs Maravai LifeSciences

CYRX and MRVI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CYRX and MRVI compare

Maravai LifeSciences is the larger company, worth 1.9 times as much as Cryoport ($1.9B against $1000M).

Cryoport grew revenue faster over the last twelve months (12.1% versus −5.0% for Maravai LifeSciences).

Cryoport keeps more of each dollar of sales as profit, with a net margin of −20.1% compared with −37.1% at Maravai LifeSciences.

Cryoport scores higher on the StockData Score (11 against 7 for Maravai LifeSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCYRXMRVI
Size and price
Market cap$1000M$1.9B
Share price$19.74$7.28
Change, 1 year128%100%
Change, 5 years−70.3%−82.5%
Beta (5Y)1.430.31
Employees738435
StockData Score
Total score11 (better)7
Valuation score1 (better)0
Growth score3 (better)2
Performance score3 (better)2
Health score4 (better)3
Dividend score00
Valuation
P/S5.4× (better)9.1×
P/B2.0× (better)9.2×
FCF yield−2.0%−1.9% (better)
Fair value$16.22$2.69
Margin of safety−21.7% (better)−170%
Growth
Revenue growth (TTM)12.1% (better)−5.0%
Revenue growth, 5Y average17.5% (better)−8.1%
Net income growth (TTM)−147%–
EPS growth (TTM)−164%–
Profitability
Gross margin47.1% (better)34.9%
Operating margin−21.2% (better)−56.1%
Net margin−20.1% (better)−37.1%
FCF margin−10.7% (better)−17.2%
Return on equity−7.4% (better)−32.9%
Return on invested capital−33.0%−32.4% (better)
Financial health
Debt / equity0.00 (better)0.72
Interest coverage−18.8×−4.9× (better)
Current ratio2.084.05 (better)
Altman Z-score1.404.50 (better)
Piotroski F-score5 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions93.9%55.5%
Held by insiders3.6%3.6%
Insider net buying, 12 months−$6.3M$115K (better)
Short interest, % of float7.1%5.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.